首頁 > 市場調查報告書 > 醫療設備

婦科治療

市場調查報告書

商品編碼

1477217

子宮肌瘤治療藥物市場，依肌瘤類型，依藥物類型，依配銷通路，依地理位置

Uterine Fibroids Treatment Drugs Market, By Fibroid Type, By Drug Type, By Distribution Channel, By Geography

出版日期: 2024年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

子宮肌瘤治療藥物市場預計 2024 年價值 18.7 億美元，預計到 2031 年將達到 31.9 億美元，2024 年至 2031 年年複合成長率(CAGR) 為 7.9%。

報告範圍		報告詳情
基準年：	2023年	2024 年市場規模：	18.7 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測 2024 年至 2031 年複合年成長率：	7.90%	2031 年價值預測：	31.9 億美元

圖 1. 2024 年子宮肌瘤治療藥物市場佔有率 (%)（依地區）

子宮肌瘤是女性子宮內或子宮上生長的非癌性腫瘤。肌瘤引起的症狀嚴重程度各不相同，包括月經量多或疼痛、下腹部壓力或疼痛、頻尿等。手術治療是一種選擇，但存在風險。因此，無需手術即可縮小或消除肌瘤的藥物療法對許多患者來說是一個有吸引力的選擇。隨著研究人員致力於開發新療法，全球子宮肌瘤治療藥物市場提供了充滿希望的成長機會。

市場動態：

女性子宮肌瘤盛行率不斷上升，加上對非侵入性治療方案的需求，是推動子宮肌瘤治療藥物市場成長的關鍵因素。根據婦女健康辦公室 2021 年 2 月發布的新聞稿，大約 20-80% 的女性在 50 歲時會患上肌瘤此外，與外科手術相關的局限性和風險正在進一步推動對藥物療法的研究。然而，藥物開發的高成本構成了課題。此外，發展中國家對肌瘤治療方案缺乏認知也限制了市場擴張。同時，臨床試驗中新興的口服療法預計將提供新的機會。

研究的主要特點：

該報告對全球子宮肌瘤治療藥物市場進行了深入分析，並提供了預測期（2024-2031）的市場規模（十億美元）和年複合成長率（CAGR%），以2023年為基準年。
它闡明了不同區隔市場的潛在收入成長機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數介紹了全球子宮肌瘤治療藥物市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球子宮肌瘤治療藥物市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球子宮肌瘤治療藥物市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳洲
韓國
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
北非
中非
南非

第 9 章：競爭格局

公司簡介
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

第 10 章：分析師觀點

命運之輪
分析師觀點
連貫的機會圖

第 11 章：參考文獻與研究方法

參考
研究方法論

簡介目錄

Product Code: CMI6788

The uterine fibroids treatment drugs market is estimated to be valued at USD 1.87 Bn in 2024 and is expected to reach USD 3.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.87 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	7.90%	2031 Value Projection:	US$ 3.19 Bn

Figure 1.Uterine Fibroids Treatment Drugs Market Share (%), By Region, 2024

Uterine Fibroids Treatment Drugs Market - IMG1

Uterine fibroids are non-cancerous tumors that grow in or on a woman's uterus. Symptoms caused by fibroids vary in severity and include heavy or painful periods, pressure or pain in the lower abdomen, frequent urination, etc. Over-the-counter medications like ibuprofen can help relieve symptoms but do not address the underlying cause. Surgical procedures are an option but carry risks. Therefore, drug therapies that can shrink or eliminate fibroids without surgery present an attractive option for many patients. The global uterine fibroids treatment drugs market offers promising growth opportunities as researchers work to develop novel therapies.

Market Dynamics:

The growing prevalence of uterine fibroids among women coupled with the demand for non-invasive treatment options is a key factor fueling the uterine fibroids treatment drugs market growth. As per Office on Women's Health press release published in February 2021, around 20-80% women develop fibroids by the age of 50. Moreover, the limitations and risks associated with surgical procedures are further driving research into pharmaceutical therapies. However, the high costs involved in drug development pose a challenge. Additionally, lack of awareness about fibroid treatment options in developing nations also restrains market expansion. Meanwhile, emerging oral therapies in the clinical trial pipeline are expected to provide new opportunities.

Key Features of the Study:

This report provides an in-depth analysis of the global uterine fibroids treatment drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global uterine fibroids treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global uterine fibroids treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global uterine fibroids treatment drugs market.

Market Segmentation

Fibroid Type:
- Intramural fibroids
- Submucosal fibroids
- Subserosal fibroids
- Others
Drug Type:
- Gonadotropin-releasing hormone (GnRH) antagonists
- Gonadotropin-releasing hormone (GnRH) agonists
- Progesterone & Contraceptives
- Hormonal Medications
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Fibroid Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Uterine Fibroids Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Uterine Fibroids Treatment Drugs Market, By Fibroid Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Intramural fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Submucosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Subserosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Uterine Fibroids Treatment Drugs Market, By Drug Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Gonadotropin-releasing hormone (GnRH) antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Gonadotropin-releasing hormone (GnRH) agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Progesterone & Contraceptives
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Hormonal Medications
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Uterine Fibroids Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Uterine Fibroids Treatment Drugs Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Myovant Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics